Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 469-473

  Burgoyne, Robert W ^a,b   Tan, Darrell H S ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

AIDS; Drug toxicities; QOL

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

AGGRESSION; ANEMIA; BLOATING; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERSENSITIVITY; INJECTION SITE PAIN; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MANIA; MENTAL DISEASE; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; OUTCOME ASSESSMENT; PANCREATITIS; PARANOIA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RASH; SIDE EFFECT; SUICIDAL IDEATION; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; LIFE SUPPORT CARE; QUALITY OF LIFE;

EID: 40049101860     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm499     Document Type: Editorial

References (66)

1. UNAIDS. Report on the Global AIDS Epidemic 2006. Geneva: UNAIDS, 2006.
2. Hogg RS, Heath K, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiviral therapy. JAMA 1998; 279: 450-4.
3. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
4. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-46.
5. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
6. Smith K, Weinberg W, De Jesus E et al. Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naive HIV-infected patients: 24-week results from COL103952 (ALERT). In: 6th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco California, 2006. Abstract H-1670a.
7. Eron J, Jr, Yeni P, Gathe J et al The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomized non-inferiority trial. Lancet 2006; 368: 476-82.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October, 2006.
9. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296: 827-43.
10. Boehringer-Ingelheim. Aptivus® (tipranavir) capsules, 250 mg. Prescribing information at aptivus.com; accessed 25 May 2007.
11. Valdez Madruga J, Lafeuillade A, Beatty G et al. TMC114/r is well tolerated by treatment-experienced patients in POWER 1, 2 and 3: integrated clinical safety analysis. In: XVI International AIDS Conference, Toronto, Canada, 2006. Abstract TUPE0062.
12. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, etricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
13. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13: 943-50.
14. Sullivan PS, Hanson DL, Chu SY et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infeced persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance report. Blood 1998; 91: 301-8.
15. Carr A. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003; 361: 726-35.
16. Nelson M, Arasteh K, Clotet B et al. Durable efficacy of erfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404-12.
17. Harris M, Joy R, Larsen G et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006; 20: 719-23.
18. Rauch A, Nolan, D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006; 43 99-102.
19. Lochet P, Peyriere H, Lotthe A et al. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4: 62-6.
20. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
21. Reisler R, Liou S, Servoss J et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials ACTG Liver Diseases Focus Group. In: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001. Abstract 43.
22. Hitti J, Frenkel LM, Stek AM et al. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36: 772-6.
23. Stern JO, Robinson PA, Love J et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl 1: S21-33.
24. Badia X, Podzamczer D, Garcia M et al. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. AIDS 1999; 13: 1727-35.
25. Burgoyne R, Rourke S, Behrens D et al. Long-term quality of life outcomes among adults living with HIV in the HAART era: The interplay of changes in clinical factors and symptom profile. AIDS Behav 2004; 8: 151-63.
26. Burgoyne. R, Saunders D. Quality of life among urban Canadian HIV/AIDS clinic outpatients. Int J STD AIDS 2001; 12: 505-12.
27. Carrieri P, Spire B, Duran S et al. Health-related quality of life after 1 year of highly active antiretroviral therapy: J Acquir Immune Defic Syndr 2003; 32: 38-47.
28. Cunningham W, Shapiro M, Hays R et al. Constitutional Symptoms and health-related quality of life in patients with symptomatic HIV disease. Am J Med 1998; 104: 129-3.
29. Murri R, Ammassari A, Fantoni M et al. Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV health survey. J AIDS Hum Retrovirol 1997; 16: 350-6.
30. Lorenz KA, Cunningham WE, Spritzer KL et al. Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV. Qual Life Res 2006; 15: 951-8.
31. Preau M, Leport C, Salmon-Ceron D et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care 2004; 16: 649-61.
32. Saunders D, Burgoyne R. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS 2002; 13: 683-90.
33. Vogl D, Rosenfeld B, Breitbart W et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999; 18: 253-62.
34. Wachtel T, Piette J, Mor V et al. Quality of life in persons with human immunodeficiency virus infection: Measurement by the medical outcomes study instrument. Ann Intern Med 1992; 116: 129-37.
35. Wu A, Rubin H, Mathews W et al. A health status questionnaire using 30 items from the medical outcomes study. Med Care 1991; 29: 786-98.
36. Burgoyne R, Renwick R. Social support and quality of life over time among adults living with HIV in the HAART era. Soc Sci Med 2004; 58: 1353-66.
37. De Boer JB, Sprangers MA, Aaronson NK et al. The feasibility, reliability and validity of the EORTC QLQ-C30 in assessing the quality of life of patients with a symptomatic HIV infection or AIDS. Psychol Health 1994; 9: 65-77.
38. Lubeck DP, Fries JF. Changes in health status after one year for persons at-risk for and with HIV infection. Psychol Health 1994; 9: 79-92.
39. Lubeck DP, Fries JF. Assessment of quality of life in early stage HIV-infected persons: Data from the AIDS time-oriented health outcome study (ATHOS). Qual Life Res 1997; 6: 494-506.
40. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995; 33: AS173-82.
41. Scott-Lennox JA, Mills RJ, Burt MS. Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life. Ann Pharmacother 1998; 32: 525-9.
42. Tsevat J, Solzan JG, Kuntz KM et al. Health values of patients infected with human, immunodeficiency virus. Med Care 1996; 34 44-57.
43. Wu AW, Rubin HR, Mathews WC et al. Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr 1993; 6 452-8.
44. Chan K, Revicki DA. Changes in surrogate laboratory markers clinical endpoints health-related quality of life in patients infected with the human immunodeficiency virus. Eval Health Prof 1998; 21: 265-81.
45. Cohen C, Revicki DA, Nabulsi A et al. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS 1998; 12: 1495-502.
46. Low-Beer S, Chan K, Wood E et al. Health related quality of life among persons with HIV after the use of protease inhibitors. Qual Life Res 2001; 9:941-9.
47. Revicki DA, Moyle G, Stellbrink HJ et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 counts between 50 and 350 per cubic millimeter. AIDS 1999; 13: 851-8.
48. Weinfurt KP, Willke RJ, Glick HA et al. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care 2000; 38: 404-10.
49. Zinkernagel C, Ledergerber B, Battegay M et al. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. AIDS 2000; 13: 1587-9.
50. Nieuwkerk PT, Gisolf EH, Colebunders R et al. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. AIDS 2000; 14: 181-7.
51. Nieuwkerk PT, Gisolf EH, Reijers MH et al. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001; 15: 1985-91.
52. Rabkin JG, Ferrando SJ, Lin S et al. Psychological effects of HAART: A 2-year study. Psychosom Med 2000; 62: 413-22.
53. Lubeck DP, Bennett CL, Mazonson PD et al. Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr 1993; 6: 478-84.
54. Wachtel T, Piette J, Mor V. Quality of life in persons with human immunodeficiency virus infection: Measurement by the medical outcomes study instrument. Ann Intern Med 1992; 116: 129-37.
55. Tramarin A, Parise N, Campostrini S et al. Association between diarrhea and quality of life in HIV-infected patients receiving highly. active antiretroviral therapy. Qual Life Res 2004; 13: 243-50.
56. Snijders F, De Boer JB, Steenbergen B et al. Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients. AIDS Care 1998; 10: 629-67.
57. Rachlis A, Gill CJ, Baril J et al. Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: A pilot study. HIV Clin Trials 2005; 6: 203-12.
58. Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 Suppl 2: S110-S114.
59. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000; 10: 546-50.
60. Dukers H, Stolte I, Albrecht N et al. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men [Letter]. AIDS 2001; 15: 812-3.
61. Oette M, Juretzko P, Kroidl A et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Pat Care 2002; 16: 413-7.
62. Power R, Tate H, McGill S et al. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79: 137-41.
63. Blanch J, Rousaud A, Martinez E et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr 2002; 31: 404-7.
64. Paton N, Earnest A, Ng Y. et al. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: Prevalence, associated factors and psychological impact. Clin Infect Dis 2002; 35: 1244-9.
65. Burgoyne R, Collins, E, Wagner C et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res 2005; 14: 981-90.
66. Guaraldi G, Orlando G, Murri R et al. Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire. Qual Life Res 2006; 15: 73-8.